サイクロデクストリンインクルージョン複合体を含む二相溶解マイクロニードルで,溶解性が低い薬剤の投与を強化します
Runze Wang1, Jiaqi Cao1, Jing Zou1
1School of Pharmaceutical Sciences, Zhengzhou University Zhengzhou Henan China guo5566@126.com.
RSC advances
|February 16, 2026
まとめ
この研究では,フルビプロフェン (FB) の皮膚経薬剤投与を強化するために,ヒドロキシプロピル-β-サイクロデクストリン (HP-β-CD) を使用した新しい溶解マイクロニードル (DMN) システムを導入しています. 開発されたDMNは,商用パッチと比較して,薬物の負荷と生物学的利用性を大幅に改善します.
科学分野:
- バイオマテリアル科学 バイオマテリアル科学
- 医薬品 製薬について
- 薬物の配送システムです.
背景:
- 溶解マイクロニードル (DMN) は,皮膚経由の薬剤投与に希望を示していますが,薬剤の負荷能力の制限に直面しています.
- 溶解性が低い薬剤は,効果的に皮膚経由で投与するには大きな課題となります.
研究 の 目的:
- 溶解性が低い薬であるフルビプロフェン (FB) の皮膚経投与のための高容量DMNプラットフォームを開発する.
- HP-β-CDインクルージョンと二相マイクロニードル設計を使用して,薬物負荷を高め,薬理学プロフィールを改善します.
主な方法:
- フルビプロフェン (FB) の充填のために,ヒドロキシプロピル-β-サイクロデクストリン (HP-β-CD) を含む二相DMNの製造.
- マイクロニードルの形態学,機械的強度,および薬物の放出運動の特徴.
- ネズミの皮膚を用いたインビトロ浸透試験と,DMNを商業用ゲルパッチと比較したネズミでのインビボ薬動学試験.
主要な成果:
- マイクロニードルは,皮膚を貫通するのに十分な機械的強度 (0.58 ± 0.10 N 断裂力) を示しました.
- 100針のパッチあたり2.67 ± 0.11 mg) を達成した.
- In vivo試験では,商業用ゲルパッチと比較して,生体利用度が2.6倍,Tmaxがより早く (2時間対8時間) 増加することが示されました.
結論:
- FB/HP-β-CDインクルージョンの二相DMNシステムは,溶解性が低い薬剤の皮膚経送量を効果的に強化します.
- このプラットフォームは,DMNの臨床翻訳と商業化の限界を克服するための有望な戦略を提供します.
関連する概念動画
Site-Targeted Drug Delivery Systems: Polymeric Carriers
17
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
17
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.8K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.8K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
227
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
227
Bioavailability Enhancement: Drug Permeability Enhancement
216
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
216
Transdermal Drug Delivery Systems
23
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
23
Modified-Release Drug Delivery Systems: Rate-Programmed II
6
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
6


